C12orf45

Across TCGA pan-cancer cohorts, C12orf45 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of C12orf45’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where C12orf45 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types C12orf45 is over-expressed in tumor.

CCRCC, LUAD, and LSCC are the cancer types where C12orf45 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C12orf45 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.361	<.001	11	view →
LUAD	Male	II,III,IV	+0.754	<.001	9	view →
LSCC	Male	II,III,IV	+0.844	<.001	8	view →
HNSC	All	IV	+0.382	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

C12orf45–CCRCC

Open the CCRCC breakdown →